Needham raised the firm’s price target on Neumora Therapeutics (NMRA) to $8 from $6 and keeps a Buy rating on the shares. The firm is more positive on Neumora following its R&D Investor Event which underscored its broad pipeline beyond navacaprant leveraging best in class pharmacology, and brain penetrant chemistry, targeting novel mechanisms with potential to improve current standard of care, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
- Neumora Therapeutics Advances MDD Treatment with Long-term Study
- Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder
- Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment
- Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim